ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
5 announcements with these filters
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.
Vimta Labs reported Q4 FY26 revenue of ₹1,120M (+16.6% YoY) and FY26 revenue of ₹4,163M (+19.5% YoY). Strategy focuses on core pharma/food testing and entry into biologics.
Vimta Labs reported Q4 FY26 revenue of ₹1,120 Mn and PAT of ₹211 Mn with strong margins across TIC segments.
Vimta Labs reported strong FY26 performance with Total Income reaching ₹4,163 Mn, up 19.5% YoY, and PAT at ₹775 Mn. Strategy focuses on expanding TIC services across Pharma, Food, and Electronics sectors.